Coibamide A Isolation for Potent Antiproliferative Activity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer treatments are limited in effectively targeting and eradicating metastatic cancers, with chemotherapy being a focus but still resulting in variable success rates, and there is a need for novel, potent cancer chemotherapeutic agents.

Innovation Solution

The isolation and purification of a novel antiproliferative compound, Coibamide A, from a Panamanian marine cyanobacterium, which is structurally elucidated and tested for its biological activity against various cancer cell lines, potentially used in compositions with chemotherapeutic agents for cancer treatment.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional chemotherapy agents are used to treat cancer, then cancer cell proliferation is inhibited, but treatment success rates remain variable and many metastatic cancers cannot be effectively eradicated

Engineering Contradiction:

Improvetreatment success rateVSAvoideffectiveness against different cancer types

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent introduces Coibamide A, a novel compound with distinct chemical structure parameters compared to conventional chemotherapy agents. The molecule features a unique macrocyclic lactone structure with specific functional groups that enable it to interact with different cellular targets, thereby improving treatment reliability across various cancer types through parameter changes in chemical composition and molecular architecture

Inventive Principle:

Principle #35Parameter changes

2Reliability

If natural products are used as cancer therapeutics, then potent antiproliferative activity is achieved, but isolation and purification processes are complex and time-consuming

Engineering Contradiction:

Improveantiproliferative activityVSAvoidisolation and purification efficiency

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent employs preliminary fractionation of the cyanobacterial extract using solid-phase extraction (SPE) cartridges before HPLC purification. This preliminary action concentrates the active compound and removes bulk impurities, thereby maintaining the potent antiproliferative activity of Coibamide A while significantly improving the efficiency and productivity of the overall isolation and purification process

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS8034780B2Isolation, purification, and structure elucidation of the antiproliferative compound coibamide A

Publication Date: 2011.10.11 UNIV OF CALIFORNIA SAN DIEGO

AI summary

Novel antiproliferative compounds, compositions comprising the same, and methods of use thereof are disclosed.